Gyre Therapeutics Inc (GYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 37,070 | 11,813 | 33,509 | 25,175 | 44,347 |
| Marketable Securities | 15,355 | 14,858 | N/A | N/A | 2,504 |
| Receivables | 31,308 | 24,780 | 16,450 | 17,136 | 1,818 |
| Inventories | 10,171 | 6,337 | 4,281 | 6,122 | N/A |
| Other current assets | 7,127 | 5,809 | 1,434 | 843 | 0 |
| TOTAL | $102,369 | $64,786 | $57,221 | $49,653 | $51,476 |
| Non-Current Assets | |||||
| PPE Net | 23,599 | 23,880 | 23,288 | 17,709 | 970 |
| Investments And Advances | 23,516 | 24,568 | 23,431 | 7,394 | 0 |
| Intangibles | 6,152 | 1,705 | 1,698 | 1,856 | 0 |
| Other Non-Current Assets | 10,496 | 10,467 | 10,901 | 8,141 | 3,216 |
| TOTAL | $63,763 | $60,620 | $59,318 | $35,100 | $4,186 |
| Total Assets | $166,132 | $125,406 | $116,539 | $84,753 | $55,662 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 351 | 335 | 2,809 | 240 | 6,419 |
| Accrued Expenses | 14,345 | 10,615 | 11,935 | 9,264 | 1,467 |
| Other current liabilities | 14 | 5,022 | 39 | N/A | N/A |
| TOTAL | $18,286 | $19,516 | $20,047 | $12,242 | $14,165 |
| Non-Current Liabilities | |||||
| Deferred Revenues | N/A | N/A | N/A | 145 | 230 |
| Other Non-Current Liabilities | 711 | 1,675 | 10,565 | -1,718 | 408 |
| TOTAL | $5,564 | $7,488 | $18,018 | $294 | $408 |
| Total Liabilities | $23,850 | $27,004 | $38,065 | $12,536 | $14,573 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 96,964 | 93,612 | 85,423 | 2,519 | 2,100 |
| Common Shares | 91 | 86 | 77 | 64 | 31 |
| Retained earnings | -68,426 | -73,453 | -85,538 | 7,395 | -402,694 |
| Other shareholders' equity | 38,570 | 35,584 | 95,756 | 31,963 | 0 |
| TOTAL | $142,282 | $98,402 | $78,474 | $72,217 | $41,089 |
| Total Liabilities And Equity | $166,132 | $125,406 | $116,539 | $84,753 | $55,662 |